“This amendment would further address PBMs opaque and overly confusing role in the drug supply chain. It would reduce perverse incentives to ensure that PBM business models benefit patients and lower costs of medications at the pharmacy counter and through the entire supply chain."
"This is the cost the insurers can charge because of a rebate system where middlemen, PBMs, use this system to raise list prices of drugs.”